nodes	percent_of_prediction	percent_of_DWPC	metapath
Olmesartan—ABCC2—Daunorubicin—hematologic cancer	0.0964	0.19	CbGbCtD
Olmesartan—SLCO1B1—Irinotecan—hematologic cancer	0.0525	0.104	CbGbCtD
Olmesartan—SLCO1B3—Methotrexate—hematologic cancer	0.0477	0.0942	CbGbCtD
Olmesartan—ABCC2—Irinotecan—hematologic cancer	0.0461	0.0911	CbGbCtD
Olmesartan—ABCC2—Vinblastine—hematologic cancer	0.041	0.081	CbGbCtD
Olmesartan—ABCC2—Vincristine—hematologic cancer	0.0403	0.0796	CbGbCtD
Olmesartan—ABCC2—Cisplatin—hematologic cancer	0.0376	0.0743	CbGbCtD
Olmesartan—ABCC2—Etoposide—hematologic cancer	0.0369	0.073	CbGbCtD
Olmesartan—ABCC2—Dexamethasone—hematologic cancer	0.0304	0.06	CbGbCtD
Olmesartan—SLCO1B1—Methotrexate—hematologic cancer	0.0278	0.0549	CbGbCtD
Olmesartan—ABCC2—Doxorubicin—hematologic cancer	0.0252	0.0498	CbGbCtD
Olmesartan—ABCC2—Methotrexate—hematologic cancer	0.0244	0.0482	CbGbCtD
Olmesartan—Irbesartan—JUN—hematologic cancer	0.00176	0.401	CrCbGaD
Olmesartan—AGTR1—hematopoietic system—hematologic cancer	0.000793	0.145	CbGeAlD
Olmesartan—SLCO1B3—lung—hematologic cancer	0.000759	0.139	CbGeAlD
Olmesartan—SLCO1B1—hematopoietic system—hematologic cancer	0.000756	0.138	CbGeAlD
Olmesartan—Telmisartan—ABCG2—hematologic cancer	0.000737	0.167	CrCbGaD
Olmesartan—Losartan—UGT1A1—hematologic cancer	0.000681	0.155	CrCbGaD
Olmesartan—AGTR1—blood—hematologic cancer	0.000525	0.0961	CbGeAlD
Olmesartan—SLCO1B1—blood—hematologic cancer	0.000501	0.0916	CbGeAlD
Olmesartan—AGTR1—lung—hematologic cancer	0.00046	0.0842	CbGeAlD
Olmesartan—AGTR1—testis—hematologic cancer	0.000434	0.0795	CbGeAlD
Olmesartan—ABCC2—blood—hematologic cancer	0.00038	0.0695	CbGeAlD
Olmesartan—Valsartan—ALB—hematologic cancer	0.000342	0.0776	CrCbGaD
Olmesartan—AGTR1—lymph node—hematologic cancer	0.000315	0.0576	CbGeAlD
Olmesartan—ABCC2—testis—hematologic cancer	0.000314	0.0575	CbGeAlD
Olmesartan—Telmisartan—ABCB1—hematologic cancer	0.000307	0.0696	CrCbGaD
Olmesartan—Candesartan—ABCB1—hematologic cancer	0.000247	0.0561	CrCbGaD
Olmesartan—ABCC2—lymph node—hematologic cancer	0.000228	0.0416	CbGeAlD
Olmesartan—Losartan—ALB—hematologic cancer	0.000167	0.0379	CrCbGaD
Olmesartan—Losartan—ABCB1—hematologic cancer	0.000159	0.0362	CrCbGaD
Olmesartan—AGTR1—Signaling Pathways—CMA1—hematologic cancer	4.52e-05	0.000461	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TRIO—hematologic cancer	4.52e-05	0.000461	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TRH—hematologic cancer	4.52e-05	0.000461	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—MTAP—hematologic cancer	4.49e-05	0.000458	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—UGT1A1—hematologic cancer	4.43e-05	0.000452	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SPHK1—hematologic cancer	4.42e-05	0.000451	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—AGO2—hematologic cancer	4.42e-05	0.000451	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—CYCS—hematologic cancer	4.39e-05	0.000448	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—LPAR1—hematologic cancer	4.37e-05	0.000446	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HDAC9—hematologic cancer	4.37e-05	0.000446	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—H3F3B—hematologic cancer	4.33e-05	0.000442	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CRABP1—hematologic cancer	4.31e-05	0.00044	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—SLC22A1—hematologic cancer	4.31e-05	0.00044	CbGpPWpGaD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—ALB—hematologic cancer	4.23e-05	0.000432	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ALOX5—hematologic cancer	4.2e-05	0.000428	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—hematologic cancer	4.19e-05	0.000427	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—GRB2—hematologic cancer	4.18e-05	0.000426	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—CYCS—hematologic cancer	4.12e-05	0.00042	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CSF2—hematologic cancer	4.11e-05	0.000419	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—NUP98—hematologic cancer	4.07e-05	0.000415	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CNR2—hematologic cancer	4.02e-05	0.000411	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PDE4B—hematologic cancer	4.02e-05	0.000411	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—hematologic cancer	4.01e-05	0.000409	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—FHL2—hematologic cancer	4e-05	0.000409	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FGF19—hematologic cancer	3.99e-05	0.000407	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PRKCG—hematologic cancer	3.97e-05	0.000405	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—JAK1—hematologic cancer	3.97e-05	0.000405	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—RAC2—hematologic cancer	3.96e-05	0.000404	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ADCY7—hematologic cancer	3.95e-05	0.000403	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—NCOA3—hematologic cancer	3.95e-05	0.000403	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—DKK1—hematologic cancer	3.93e-05	0.000401	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—AGRN—hematologic cancer	3.93e-05	0.000401	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—NUP214—hematologic cancer	3.92e-05	0.0004	CbGpPWpGaD
Olmesartan—Angiopathy—Epirubicin—hematologic cancer	3.9e-05	0.000101	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—STAT5B—hematologic cancer	3.9e-05	0.000398	CbGpPWpGaD
Olmesartan—Urethral disorder—Doxorubicin—hematologic cancer	3.9e-05	0.000101	CcSEcCtD
Olmesartan—Decreased appetite—Betamethasone—hematologic cancer	3.9e-05	0.000101	CcSEcCtD
Olmesartan—Decreased appetite—Dexamethasone—hematologic cancer	3.9e-05	0.000101	CcSEcCtD
Olmesartan—Nausea—Mitoxantrone—hematologic cancer	3.89e-05	0.000101	CcSEcCtD
Olmesartan—Nausea—Irinotecan—hematologic cancer	3.89e-05	0.000101	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	3.88e-05	0.000396	CbGpPWpGaD
Olmesartan—Infection—Prednisone—hematologic cancer	3.88e-05	0.000101	CcSEcCtD
Olmesartan—Mediastinal disorder—Epirubicin—hematologic cancer	3.87e-05	0.0001	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.87e-05	0.0001	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.87e-05	0.0001	CcSEcCtD
Olmesartan—Back pain—Methotrexate—hematologic cancer	3.87e-05	0.0001	CcSEcCtD
Olmesartan—Fatigue—Dexamethasone—hematologic cancer	3.86e-05	0.0001	CcSEcCtD
Olmesartan—Fatigue—Betamethasone—hematologic cancer	3.86e-05	0.0001	CcSEcCtD
Olmesartan—Pruritus—Etoposide—hematologic cancer	3.85e-05	9.99e-05	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—MTR—hematologic cancer	3.84e-05	0.000392	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ABCG2—hematologic cancer	3.84e-05	0.000392	CbGpPWpGaD
Olmesartan—Shock—Prednisone—hematologic cancer	3.84e-05	9.95e-05	CcSEcCtD
Olmesartan—Arrhythmia—Epirubicin—hematologic cancer	3.84e-05	9.95e-05	CcSEcCtD
Olmesartan—Pain—Dexamethasone—hematologic cancer	3.83e-05	9.93e-05	CcSEcCtD
Olmesartan—Pain—Betamethasone—hematologic cancer	3.83e-05	9.93e-05	CcSEcCtD
Olmesartan—Nervous system disorder—Prednisone—hematologic cancer	3.83e-05	9.92e-05	CcSEcCtD
Olmesartan—Tachycardia—Prednisone—hematologic cancer	3.81e-05	9.87e-05	CcSEcCtD
Olmesartan—Alopecia—Epirubicin—hematologic cancer	3.8e-05	9.84e-05	CcSEcCtD
Olmesartan—Skin disorder—Prednisone—hematologic cancer	3.79e-05	9.83e-05	CcSEcCtD
Olmesartan—Nausea—Gemcitabine—hematologic cancer	3.79e-05	9.82e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—ADCY7—hematologic cancer	3.78e-05	0.000386	CbGpPWpGaD
Olmesartan—Vomiting—Cisplatin—hematologic cancer	3.78e-05	9.8e-05	CcSEcCtD
Olmesartan—Hyperhidrosis—Prednisone—hematologic cancer	3.77e-05	9.78e-05	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—ENO2—hematologic cancer	3.77e-05	0.000384	CbGpPWpGaD
Olmesartan—Vision blurred—Methotrexate—hematologic cancer	3.77e-05	9.76e-05	CcSEcCtD
Olmesartan—Mental disorder—Epirubicin—hematologic cancer	3.76e-05	9.76e-05	CcSEcCtD
Olmesartan—Rash—Cisplatin—hematologic cancer	3.75e-05	9.71e-05	CcSEcCtD
Olmesartan—Dermatitis—Cisplatin—hematologic cancer	3.74e-05	9.71e-05	CcSEcCtD
Olmesartan—Malnutrition—Epirubicin—hematologic cancer	3.74e-05	9.69e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—CSF2—hematologic cancer	3.73e-05	0.000381	CbGpPWpGaD
Olmesartan—Diarrhoea—Etoposide—hematologic cancer	3.73e-05	9.66e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—IDH2—hematologic cancer	3.72e-05	0.00038	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—HMMR—hematologic cancer	3.72e-05	0.00038	CbGpPWpGaD
Olmesartan—Anorexia—Prednisone—hematologic cancer	3.72e-05	9.64e-05	CcSEcCtD
Olmesartan—Ill-defined disorder—Methotrexate—hematologic cancer	3.71e-05	9.61e-05	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—IL2RA—hematologic cancer	3.71e-05	0.000378	CbGpPWpGaD
Olmesartan—Anaemia—Methotrexate—hematologic cancer	3.69e-05	9.57e-05	CcSEcCtD
Olmesartan—Feeling abnormal—Betamethasone—hematologic cancer	3.69e-05	9.57e-05	CcSEcCtD
Olmesartan—Feeling abnormal—Dexamethasone—hematologic cancer	3.69e-05	9.57e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—XIAP—hematologic cancer	3.68e-05	0.000375	CbGpPWpGaD
Olmesartan—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.66e-05	9.5e-05	CcSEcCtD
Olmesartan—Gastrointestinal pain—Betamethasone—hematologic cancer	3.66e-05	9.5e-05	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ABCB1—hematologic cancer	3.66e-05	0.000373	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTT1—hematologic cancer	3.65e-05	0.000373	CbGpPWpGaD
Olmesartan—Back pain—Epirubicin—hematologic cancer	3.62e-05	9.38e-05	CcSEcCtD
Olmesartan—Angiopathy—Doxorubicin—hematologic cancer	3.61e-05	9.35e-05	CcSEcCtD
Olmesartan—Malaise—Methotrexate—hematologic cancer	3.6e-05	9.34e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—PRKCG—hematologic cancer	3.6e-05	0.000368	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—JAK1—hematologic cancer	3.6e-05	0.000368	CbGpPWpGaD
Olmesartan—Dizziness—Etoposide—hematologic cancer	3.6e-05	9.33e-05	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.6e-05	0.000367	CbGpPWpGaD
Olmesartan—Muscle spasms—Epirubicin—hematologic cancer	3.6e-05	9.32e-05	CcSEcCtD
Olmesartan—Vertigo—Methotrexate—hematologic cancer	3.59e-05	9.31e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—SMARCA4—hematologic cancer	3.59e-05	0.000366	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SH2B3—hematologic cancer	3.59e-05	0.000366	CbGpPWpGaD
Olmesartan—Mediastinal disorder—Doxorubicin—hematologic cancer	3.58e-05	9.29e-05	CcSEcCtD
Olmesartan—Leukopenia—Methotrexate—hematologic cancer	3.58e-05	9.27e-05	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—SDC1—hematologic cancer	3.57e-05	0.000364	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GZMB—hematologic cancer	3.56e-05	0.000364	CbGpPWpGaD
Olmesartan—Urticaria—Dexamethasone—hematologic cancer	3.56e-05	9.23e-05	CcSEcCtD
Olmesartan—Urticaria—Betamethasone—hematologic cancer	3.56e-05	9.23e-05	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.56e-05	9.22e-05	CcSEcCtD
Olmesartan—Dizziness—Prednisolone—hematologic cancer	3.55e-05	9.21e-05	CcSEcCtD
Olmesartan—Arrhythmia—Doxorubicin—hematologic cancer	3.55e-05	9.21e-05	CcSEcCtD
Olmesartan—Asthenia—Triamcinolone—hematologic cancer	3.54e-05	9.19e-05	CcSEcCtD
Olmesartan—Body temperature increased—Dexamethasone—hematologic cancer	3.54e-05	9.18e-05	CcSEcCtD
Olmesartan—Body temperature increased—Betamethasone—hematologic cancer	3.54e-05	9.18e-05	CcSEcCtD
Olmesartan—Abdominal pain—Betamethasone—hematologic cancer	3.54e-05	9.18e-05	CcSEcCtD
Olmesartan—Abdominal pain—Dexamethasone—hematologic cancer	3.54e-05	9.18e-05	CcSEcCtD
Olmesartan—Nausea—Cisplatin—hematologic cancer	3.53e-05	9.15e-05	CcSEcCtD
Olmesartan—Insomnia—Prednisone—hematologic cancer	3.53e-05	9.15e-05	CcSEcCtD
Olmesartan—Vision blurred—Epirubicin—hematologic cancer	3.53e-05	9.14e-05	CcSEcCtD
Olmesartan—Alopecia—Doxorubicin—hematologic cancer	3.51e-05	9.11e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	3.51e-05	0.000358	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ARNTL—hematologic cancer	3.5e-05	0.000357	CbGpPWpGaD
Olmesartan—Pruritus—Triamcinolone—hematologic cancer	3.49e-05	9.06e-05	CcSEcCtD
Olmesartan—Cough—Methotrexate—hematologic cancer	3.49e-05	9.04e-05	CcSEcCtD
Olmesartan—Mental disorder—Doxorubicin—hematologic cancer	3.48e-05	9.03e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—CTNNA1—hematologic cancer	3.48e-05	0.000355	CbGpPWpGaD
Olmesartan—Ill-defined disorder—Epirubicin—hematologic cancer	3.47e-05	8.99e-05	CcSEcCtD
Olmesartan—Vomiting—Etoposide—hematologic cancer	3.46e-05	8.97e-05	CcSEcCtD
Olmesartan—Malnutrition—Doxorubicin—hematologic cancer	3.46e-05	8.97e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—HSPB1—hematologic cancer	3.46e-05	0.000353	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCL3—hematologic cancer	3.46e-05	0.000353	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—EIF4EBP1—hematologic cancer	3.46e-05	0.000353	CbGpPWpGaD
Olmesartan—Anaemia—Epirubicin—hematologic cancer	3.46e-05	8.96e-05	CcSEcCtD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ABCB1—hematologic cancer	3.44e-05	0.000351	CbGpPWpGaD
Olmesartan—Agitation—Epirubicin—hematologic cancer	3.44e-05	8.91e-05	CcSEcCtD
Olmesartan—Dyspepsia—Prednisone—hematologic cancer	3.44e-05	8.9e-05	CcSEcCtD
Olmesartan—Rash—Etoposide—hematologic cancer	3.43e-05	8.9e-05	CcSEcCtD
Olmesartan—Dermatitis—Etoposide—hematologic cancer	3.43e-05	8.89e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—PTHLH—hematologic cancer	3.42e-05	0.000349	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SDC1—hematologic cancer	3.42e-05	0.000349	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—CREBBP—hematologic cancer	3.42e-05	0.000349	CbGpPWpGaD
Olmesartan—Headache—Etoposide—hematologic cancer	3.41e-05	8.84e-05	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3.41e-05	0.000348	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ACP5—hematologic cancer	3.41e-05	0.000347	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CA9—hematologic cancer	3.41e-05	0.000347	CbGpPWpGaD
Olmesartan—Arthralgia—Methotrexate—hematologic cancer	3.4e-05	8.82e-05	CcSEcCtD
Olmesartan—Chest pain—Methotrexate—hematologic cancer	3.4e-05	8.82e-05	CcSEcCtD
Olmesartan—Myalgia—Methotrexate—hematologic cancer	3.4e-05	8.82e-05	CcSEcCtD
Olmesartan—Decreased appetite—Prednisone—hematologic cancer	3.39e-05	8.79e-05	CcSEcCtD
Olmesartan—Rash—Prednisolone—hematologic cancer	3.39e-05	8.78e-05	CcSEcCtD
Olmesartan—Dermatitis—Prednisolone—hematologic cancer	3.38e-05	8.77e-05	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.38e-05	8.76e-05	CcSEcCtD
Olmesartan—Malaise—Epirubicin—hematologic cancer	3.37e-05	8.74e-05	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.37e-05	0.000343	CbGpPWpGaD
Olmesartan—Fatigue—Prednisone—hematologic cancer	3.37e-05	8.72e-05	CcSEcCtD
Olmesartan—Headache—Prednisolone—hematologic cancer	3.36e-05	8.72e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—IL2RA—hematologic cancer	3.36e-05	0.000343	CbGpPWpGaD
Olmesartan—Discomfort—Methotrexate—hematologic cancer	3.36e-05	8.71e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—NCOR2—hematologic cancer	3.36e-05	0.000343	CbGpPWpGaD
Olmesartan—Vertigo—Epirubicin—hematologic cancer	3.36e-05	8.71e-05	CcSEcCtD
Olmesartan—Syncope—Epirubicin—hematologic cancer	3.35e-05	8.69e-05	CcSEcCtD
Olmesartan—Leukopenia—Epirubicin—hematologic cancer	3.35e-05	8.68e-05	CcSEcCtD
Olmesartan—Back pain—Doxorubicin—hematologic cancer	3.35e-05	8.68e-05	CcSEcCtD
Olmesartan—Constipation—Prednisone—hematologic cancer	3.34e-05	8.65e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—PTGER4—hematologic cancer	3.33e-05	0.00034	CbGpPWpGaD
Olmesartan—Muscle spasms—Doxorubicin—hematologic cancer	3.33e-05	8.62e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—LCK—hematologic cancer	3.31e-05	0.000338	CbGpPWpGaD
Olmesartan—Palpitations—Epirubicin—hematologic cancer	3.31e-05	8.57e-05	CcSEcCtD
Olmesartan—Loss of consciousness—Epirubicin—hematologic cancer	3.29e-05	8.52e-05	CcSEcCtD
Olmesartan—Dizziness—Triamcinolone—hematologic cancer	3.27e-05	8.47e-05	CcSEcCtD
Olmesartan—Cough—Epirubicin—hematologic cancer	3.26e-05	8.46e-05	CcSEcCtD
Olmesartan—Anaphylactic shock—Methotrexate—hematologic cancer	3.26e-05	8.45e-05	CcSEcCtD
Olmesartan—Vision blurred—Doxorubicin—hematologic cancer	3.26e-05	8.45e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—H3F3A—hematologic cancer	3.25e-05	0.000331	CbGpPWpGaD
Olmesartan—Infection—Methotrexate—hematologic cancer	3.24e-05	8.4e-05	CcSEcCtD
Olmesartan—Nausea—Etoposide—hematologic cancer	3.23e-05	8.38e-05	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.22e-05	0.000329	CbGpPWpGaD
Olmesartan—Feeling abnormal—Prednisone—hematologic cancer	3.22e-05	8.34e-05	CcSEcCtD
Olmesartan—Asthenia—Betamethasone—hematologic cancer	3.22e-05	8.33e-05	CcSEcCtD
Olmesartan—Asthenia—Dexamethasone—hematologic cancer	3.22e-05	8.33e-05	CcSEcCtD
Olmesartan—Ill-defined disorder—Doxorubicin—hematologic cancer	3.21e-05	8.32e-05	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ALB—hematologic cancer	3.2e-05	0.000327	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—IDH1—hematologic cancer	3.2e-05	0.000327	CbGpPWpGaD
Olmesartan—Nervous system disorder—Methotrexate—hematologic cancer	3.2e-05	8.29e-05	CcSEcCtD
Olmesartan—Anaemia—Doxorubicin—hematologic cancer	3.2e-05	8.29e-05	CcSEcCtD
Olmesartan—Thrombocytopenia—Methotrexate—hematologic cancer	3.19e-05	8.28e-05	CcSEcCtD
Olmesartan—Gastrointestinal pain—Prednisone—hematologic cancer	3.19e-05	8.27e-05	CcSEcCtD
Olmesartan—Nausea—Prednisolone—hematologic cancer	3.19e-05	8.27e-05	CcSEcCtD
Olmesartan—Arthralgia—Epirubicin—hematologic cancer	3.18e-05	8.25e-05	CcSEcCtD
Olmesartan—Chest pain—Epirubicin—hematologic cancer	3.18e-05	8.25e-05	CcSEcCtD
Olmesartan—Myalgia—Epirubicin—hematologic cancer	3.18e-05	8.25e-05	CcSEcCtD
Olmesartan—Agitation—Doxorubicin—hematologic cancer	3.18e-05	8.24e-05	CcSEcCtD
Olmesartan—Anxiety—Epirubicin—hematologic cancer	3.17e-05	8.22e-05	CcSEcCtD
Olmesartan—Pruritus—Dexamethasone—hematologic cancer	3.17e-05	8.22e-05	CcSEcCtD
Olmesartan—Pruritus—Betamethasone—hematologic cancer	3.17e-05	8.22e-05	CcSEcCtD
Olmesartan—Skin disorder—Methotrexate—hematologic cancer	3.17e-05	8.21e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—GSTO1—hematologic cancer	3.17e-05	0.000323	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ABCC3—hematologic cancer	3.17e-05	0.000323	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—TXN—hematologic cancer	3.17e-05	0.000323	CbGpPWpGaD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.16e-05	8.2e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—PRKCZ—hematologic cancer	3.16e-05	0.000322	CbGpPWpGaD
Olmesartan—Hyperhidrosis—Methotrexate—hematologic cancer	3.15e-05	8.17e-05	CcSEcCtD
Olmesartan—Discomfort—Epirubicin—hematologic cancer	3.15e-05	8.15e-05	CcSEcCtD
Olmesartan—Vomiting—Triamcinolone—hematologic cancer	3.14e-05	8.14e-05	CcSEcCtD
Olmesartan—Malaise—Doxorubicin—hematologic cancer	3.12e-05	8.09e-05	CcSEcCtD
Olmesartan—Rash—Triamcinolone—hematologic cancer	3.11e-05	8.07e-05	CcSEcCtD
Olmesartan—Dermatitis—Triamcinolone—hematologic cancer	3.11e-05	8.06e-05	CcSEcCtD
Olmesartan—Vertigo—Doxorubicin—hematologic cancer	3.11e-05	8.06e-05	CcSEcCtD
Olmesartan—Anorexia—Methotrexate—hematologic cancer	3.11e-05	8.06e-05	CcSEcCtD
Olmesartan—Syncope—Doxorubicin—hematologic cancer	3.1e-05	8.04e-05	CcSEcCtD
Olmesartan—Urticaria—Prednisone—hematologic cancer	3.1e-05	8.04e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—SPHK1—hematologic cancer	3.1e-05	0.000316	CbGpPWpGaD
Olmesartan—Leukopenia—Doxorubicin—hematologic cancer	3.1e-05	8.03e-05	CcSEcCtD
Olmesartan—Headache—Triamcinolone—hematologic cancer	3.09e-05	8.02e-05	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—PIK3CG—hematologic cancer	3.09e-05	0.000315	CbGpPWpGaD
Olmesartan—Body temperature increased—Prednisone—hematologic cancer	3.09e-05	8e-05	CcSEcCtD
Olmesartan—Abdominal pain—Prednisone—hematologic cancer	3.09e-05	8e-05	CcSEcCtD
Olmesartan—Diarrhoea—Betamethasone—hematologic cancer	3.07e-05	7.95e-05	CcSEcCtD
Olmesartan—Diarrhoea—Dexamethasone—hematologic cancer	3.07e-05	7.95e-05	CcSEcCtD
Olmesartan—Palpitations—Doxorubicin—hematologic cancer	3.06e-05	7.93e-05	CcSEcCtD
Olmesartan—Oedema—Epirubicin—hematologic cancer	3.05e-05	7.91e-05	CcSEcCtD
Olmesartan—Anaphylactic shock—Epirubicin—hematologic cancer	3.05e-05	7.91e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—PARP1—hematologic cancer	3.05e-05	0.000311	CbGpPWpGaD
Olmesartan—Hypotension—Methotrexate—hematologic cancer	3.05e-05	7.9e-05	CcSEcCtD
Olmesartan—Loss of consciousness—Doxorubicin—hematologic cancer	3.04e-05	7.88e-05	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—CD44—hematologic cancer	3.04e-05	0.00031	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—NQO1—hematologic cancer	3.04e-05	0.00031	CbGpPWpGaD
Olmesartan—Infection—Epirubicin—hematologic cancer	3.03e-05	7.86e-05	CcSEcCtD
Olmesartan—Cough—Doxorubicin—hematologic cancer	3.02e-05	7.83e-05	CcSEcCtD
Olmesartan—Shock—Epirubicin—hematologic cancer	3e-05	7.78e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—FBXW7—hematologic cancer	3e-05	0.000306	CbGpPWpGaD
Olmesartan—Nervous system disorder—Epirubicin—hematologic cancer	2.99e-05	7.76e-05	CcSEcCtD
Olmesartan—Thrombocytopenia—Epirubicin—hematologic cancer	2.99e-05	7.75e-05	CcSEcCtD
Olmesartan—Tachycardia—Epirubicin—hematologic cancer	2.98e-05	7.72e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—UGT1A1—hematologic cancer	2.98e-05	0.000304	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.97e-05	0.000303	CbGpPWpGaD
Olmesartan—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.97e-05	7.7e-05	CcSEcCtD
Olmesartan—Skin disorder—Epirubicin—hematologic cancer	2.97e-05	7.69e-05	CcSEcCtD
Olmesartan—Dizziness—Dexamethasone—hematologic cancer	2.96e-05	7.68e-05	CcSEcCtD
Olmesartan—Dizziness—Betamethasone—hematologic cancer	2.96e-05	7.68e-05	CcSEcCtD
Olmesartan—Hyperhidrosis—Epirubicin—hematologic cancer	2.95e-05	7.65e-05	CcSEcCtD
Olmesartan—Insomnia—Methotrexate—hematologic cancer	2.95e-05	7.65e-05	CcSEcCtD
Olmesartan—Chest pain—Doxorubicin—hematologic cancer	2.95e-05	7.64e-05	CcSEcCtD
Olmesartan—Arthralgia—Doxorubicin—hematologic cancer	2.95e-05	7.64e-05	CcSEcCtD
Olmesartan—Myalgia—Doxorubicin—hematologic cancer	2.95e-05	7.64e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—CXCR4—hematologic cancer	2.94e-05	0.0003	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HDAC2—hematologic cancer	2.94e-05	0.0003	CbGpPWpGaD
Olmesartan—Anxiety—Doxorubicin—hematologic cancer	2.94e-05	7.61e-05	CcSEcCtD
Olmesartan—Nausea—Triamcinolone—hematologic cancer	2.93e-05	7.6e-05	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.93e-05	7.58e-05	CcSEcCtD
Olmesartan—Discomfort—Doxorubicin—hematologic cancer	2.91e-05	7.55e-05	CcSEcCtD
Olmesartan—Anorexia—Epirubicin—hematologic cancer	2.91e-05	7.54e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—CRABP1—hematologic cancer	2.9e-05	0.000295	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—SLC22A1—hematologic cancer	2.9e-05	0.000295	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYCS—hematologic cancer	2.87e-05	0.000293	CbGpPWpGaD
Olmesartan—Dyspepsia—Methotrexate—hematologic cancer	2.87e-05	7.44e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—CBL—hematologic cancer	2.87e-05	0.000293	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—HSP90AA1—hematologic cancer	2.85e-05	0.000291	CbGpPWpGaD
Olmesartan—Hypotension—Epirubicin—hematologic cancer	2.85e-05	7.39e-05	CcSEcCtD
Olmesartan—Vomiting—Betamethasone—hematologic cancer	2.85e-05	7.39e-05	CcSEcCtD
Olmesartan—Vomiting—Dexamethasone—hematologic cancer	2.85e-05	7.39e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—IL3—hematologic cancer	2.84e-05	0.000289	CbGpPWpGaD
Olmesartan—Decreased appetite—Methotrexate—hematologic cancer	2.84e-05	7.35e-05	CcSEcCtD
Olmesartan—Rash—Dexamethasone—hematologic cancer	2.83e-05	7.32e-05	CcSEcCtD
Olmesartan—Rash—Betamethasone—hematologic cancer	2.83e-05	7.32e-05	CcSEcCtD
Olmesartan—Oedema—Doxorubicin—hematologic cancer	2.82e-05	7.32e-05	CcSEcCtD
Olmesartan—Anaphylactic shock—Doxorubicin—hematologic cancer	2.82e-05	7.32e-05	CcSEcCtD
Olmesartan—Dermatitis—Dexamethasone—hematologic cancer	2.82e-05	7.32e-05	CcSEcCtD
Olmesartan—Dermatitis—Betamethasone—hematologic cancer	2.82e-05	7.32e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—ALOX5—hematologic cancer	2.82e-05	0.000288	CbGpPWpGaD
Olmesartan—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.82e-05	7.3e-05	CcSEcCtD
Olmesartan—Fatigue—Methotrexate—hematologic cancer	2.81e-05	7.29e-05	CcSEcCtD
Olmesartan—Headache—Dexamethasone—hematologic cancer	2.81e-05	7.28e-05	CcSEcCtD
Olmesartan—Headache—Betamethasone—hematologic cancer	2.81e-05	7.28e-05	CcSEcCtD
Olmesartan—Infection—Doxorubicin—hematologic cancer	2.81e-05	7.27e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—PIK3CG—hematologic cancer	2.8e-05	0.000286	CbGpPWpGaD
Olmesartan—Asthenia—Prednisone—hematologic cancer	2.8e-05	7.26e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—PTPN1—hematologic cancer	2.79e-05	0.000285	CbGpPWpGaD
Olmesartan—Pain—Methotrexate—hematologic cancer	2.79e-05	7.23e-05	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.78e-05	7.21e-05	CcSEcCtD
Olmesartan—Shock—Doxorubicin—hematologic cancer	2.78e-05	7.2e-05	CcSEcCtD
Olmesartan—Nervous system disorder—Doxorubicin—hematologic cancer	2.77e-05	7.18e-05	CcSEcCtD
Olmesartan—Thrombocytopenia—Doxorubicin—hematologic cancer	2.77e-05	7.17e-05	CcSEcCtD
Olmesartan—Pruritus—Prednisone—hematologic cancer	2.76e-05	7.16e-05	CcSEcCtD
Olmesartan—Insomnia—Epirubicin—hematologic cancer	2.76e-05	7.16e-05	CcSEcCtD
Olmesartan—Tachycardia—Doxorubicin—hematologic cancer	2.76e-05	7.14e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—PTPN11—hematologic cancer	2.75e-05	0.000281	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—RASGRP1—hematologic cancer	2.74e-05	0.00028	CbGpPWpGaD
Olmesartan—Skin disorder—Doxorubicin—hematologic cancer	2.74e-05	7.11e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—HSP90AA1—hematologic cancer	2.74e-05	0.000279	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SYK—hematologic cancer	2.74e-05	0.000279	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—NUP98—hematologic cancer	2.73e-05	0.000279	CbGpPWpGaD
Olmesartan—Hyperhidrosis—Doxorubicin—hematologic cancer	2.73e-05	7.08e-05	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—PIK3CD—hematologic cancer	2.71e-05	0.000277	CbGpPWpGaD
Olmesartan—Anorexia—Doxorubicin—hematologic cancer	2.69e-05	6.98e-05	CcSEcCtD
Olmesartan—Feeling abnormal—Methotrexate—hematologic cancer	2.69e-05	6.97e-05	CcSEcCtD
Olmesartan—Dyspepsia—Epirubicin—hematologic cancer	2.69e-05	6.96e-05	CcSEcCtD
Olmesartan—Diarrhoea—Prednisone—hematologic cancer	2.67e-05	6.92e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—CREB1—hematologic cancer	2.67e-05	0.000272	CbGpPWpGaD
Olmesartan—Gastrointestinal pain—Methotrexate—hematologic cancer	2.67e-05	6.91e-05	CcSEcCtD
Olmesartan—Nausea—Dexamethasone—hematologic cancer	2.66e-05	6.9e-05	CcSEcCtD
Olmesartan—Nausea—Betamethasone—hematologic cancer	2.66e-05	6.9e-05	CcSEcCtD
Olmesartan—Decreased appetite—Epirubicin—hematologic cancer	2.65e-05	6.88e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—ADCY7—hematologic cancer	2.65e-05	0.000271	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—NCOA3—hematologic cancer	2.65e-05	0.000271	CbGpPWpGaD
Olmesartan—Hypotension—Doxorubicin—hematologic cancer	2.64e-05	6.84e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—STAT1—hematologic cancer	2.64e-05	0.000269	CbGpPWpGaD
Olmesartan—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.64e-05	6.83e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—NUP214—hematologic cancer	2.63e-05	0.000269	CbGpPWpGaD
Olmesartan—Fatigue—Epirubicin—hematologic cancer	2.63e-05	6.82e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—CCL2—hematologic cancer	2.61e-05	0.000266	CbGpPWpGaD
Olmesartan—Constipation—Epirubicin—hematologic cancer	2.61e-05	6.77e-05	CcSEcCtD
Olmesartan—Pain—Epirubicin—hematologic cancer	2.61e-05	6.77e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	2.61e-05	0.000266	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IL6R—hematologic cancer	2.6e-05	0.000266	CbGpPWpGaD
Olmesartan—Urticaria—Methotrexate—hematologic cancer	2.59e-05	6.72e-05	CcSEcCtD
Olmesartan—Dizziness—Prednisone—hematologic cancer	2.58e-05	6.69e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—MTR—hematologic cancer	2.58e-05	0.000263	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ABCG2—hematologic cancer	2.58e-05	0.000263	CbGpPWpGaD
Olmesartan—Abdominal pain—Methotrexate—hematologic cancer	2.58e-05	6.68e-05	CcSEcCtD
Olmesartan—Body temperature increased—Methotrexate—hematologic cancer	2.58e-05	6.68e-05	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.57e-05	6.67e-05	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.57e-05	0.000262	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PIK3R1—hematologic cancer	2.56e-05	0.000261	CbGpPWpGaD
Olmesartan—Insomnia—Doxorubicin—hematologic cancer	2.55e-05	6.62e-05	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—GSTP1—hematologic cancer	2.53e-05	0.000258	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ENO2—hematologic cancer	2.53e-05	0.000258	CbGpPWpGaD
Olmesartan—Feeling abnormal—Epirubicin—hematologic cancer	2.52e-05	6.52e-05	CcSEcCtD
Olmesartan—Gastrointestinal pain—Epirubicin—hematologic cancer	2.5e-05	6.47e-05	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—JAK2—hematologic cancer	2.49e-05	0.000254	CbGpPWpGaD
Olmesartan—Dyspepsia—Doxorubicin—hematologic cancer	2.49e-05	6.44e-05	CcSEcCtD
Olmesartan—Vomiting—Prednisone—hematologic cancer	2.48e-05	6.43e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—MAP2K1—hematologic cancer	2.48e-05	0.000253	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GRB2—hematologic cancer	2.47e-05	0.000252	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PIK3CD—hematologic cancer	2.46e-05	0.000251	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PDGFA—hematologic cancer	2.46e-05	0.000251	CbGpPWpGaD
Olmesartan—Rash—Prednisone—hematologic cancer	2.46e-05	6.38e-05	CcSEcCtD
Olmesartan—Dermatitis—Prednisone—hematologic cancer	2.46e-05	6.37e-05	CcSEcCtD
Olmesartan—Decreased appetite—Doxorubicin—hematologic cancer	2.46e-05	6.36e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—GSTT1—hematologic cancer	2.45e-05	0.00025	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.45e-05	0.00025	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.45e-05	0.00025	CbGpPWpGaD
Olmesartan—Headache—Prednisone—hematologic cancer	2.45e-05	6.34e-05	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.44e-05	6.32e-05	CcSEcCtD
Olmesartan—Fatigue—Doxorubicin—hematologic cancer	2.44e-05	6.31e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—KITLG—hematologic cancer	2.43e-05	0.000248	CbGpPWpGaD
Olmesartan—Urticaria—Epirubicin—hematologic cancer	2.43e-05	6.29e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	2.42e-05	0.000247	CbGpPWpGaD
Olmesartan—Constipation—Doxorubicin—hematologic cancer	2.42e-05	6.26e-05	CcSEcCtD
Olmesartan—Pain—Doxorubicin—hematologic cancer	2.42e-05	6.26e-05	CcSEcCtD
Olmesartan—Body temperature increased—Epirubicin—hematologic cancer	2.41e-05	6.25e-05	CcSEcCtD
Olmesartan—Abdominal pain—Epirubicin—hematologic cancer	2.41e-05	6.25e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—SDC1—hematologic cancer	2.4e-05	0.000245	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ABCB1—hematologic cancer	2.4e-05	0.000245	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—STAT5A—hematologic cancer	2.37e-05	0.000242	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PIK3CB—hematologic cancer	2.37e-05	0.000241	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CDKN2B—hematologic cancer	2.35e-05	0.00024	CbGpPWpGaD
Olmesartan—Asthenia—Methotrexate—hematologic cancer	2.34e-05	6.07e-05	CcSEcCtD
Olmesartan—Feeling abnormal—Doxorubicin—hematologic cancer	2.33e-05	6.03e-05	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—NCOR1—hematologic cancer	2.33e-05	0.000237	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTM1—hematologic cancer	2.33e-05	0.000237	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PIK3R1—hematologic cancer	2.33e-05	0.000237	CbGpPWpGaD
Olmesartan—Nausea—Prednisone—hematologic cancer	2.32e-05	6.01e-05	CcSEcCtD
Olmesartan—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.31e-05	5.99e-05	CcSEcCtD
Olmesartan—Pruritus—Methotrexate—hematologic cancer	2.31e-05	5.98e-05	CcSEcCtD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.3e-05	0.000234	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	2.29e-05	0.000234	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ALB—hematologic cancer	2.29e-05	0.000234	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CD86—hematologic cancer	2.27e-05	0.000232	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	2.26e-05	0.000231	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—JAK2—hematologic cancer	2.26e-05	0.000231	CbGpPWpGaD
Olmesartan—Urticaria—Doxorubicin—hematologic cancer	2.24e-05	5.82e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—HES1—hematologic cancer	2.24e-05	0.000229	CbGpPWpGaD
Olmesartan—Abdominal pain—Doxorubicin—hematologic cancer	2.23e-05	5.79e-05	CcSEcCtD
Olmesartan—Body temperature increased—Doxorubicin—hematologic cancer	2.23e-05	5.79e-05	CcSEcCtD
Olmesartan—Diarrhoea—Methotrexate—hematologic cancer	2.23e-05	5.78e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—NCOR1—hematologic cancer	2.23e-05	0.000227	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CSF2—hematologic cancer	2.21e-05	0.000225	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FGF1—hematologic cancer	2.21e-05	0.000225	CbGpPWpGaD
Olmesartan—Asthenia—Epirubicin—hematologic cancer	2.19e-05	5.68e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—FOXO1—hematologic cancer	2.17e-05	0.000222	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—IL2—hematologic cancer	2.17e-05	0.000222	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PDGFRB—hematologic cancer	2.17e-05	0.000221	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	2.16e-05	0.000221	CbGpPWpGaD
Olmesartan—Pruritus—Epirubicin—hematologic cancer	2.16e-05	5.6e-05	CcSEcCtD
Olmesartan—Dizziness—Methotrexate—hematologic cancer	2.16e-05	5.59e-05	CcSEcCtD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ALB—hematologic cancer	2.15e-05	0.000219	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PIK3CB—hematologic cancer	2.15e-05	0.000219	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PDGFRA—hematologic cancer	2.14e-05	0.000218	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—JAK1—hematologic cancer	2.13e-05	0.000217	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PRKCG—hematologic cancer	2.13e-05	0.000217	CbGpPWpGaD
Olmesartan—Diarrhoea—Epirubicin—hematologic cancer	2.09e-05	5.41e-05	CcSEcCtD
Olmesartan—Vomiting—Methotrexate—hematologic cancer	2.07e-05	5.38e-05	CcSEcCtD
Olmesartan—Rash—Methotrexate—hematologic cancer	2.06e-05	5.33e-05	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—MTHFR—hematologic cancer	2.06e-05	0.00021	CbGpPWpGaD
Olmesartan—Dermatitis—Methotrexate—hematologic cancer	2.05e-05	5.33e-05	CcSEcCtD
Olmesartan—Headache—Methotrexate—hematologic cancer	2.04e-05	5.3e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—CD44—hematologic cancer	2.04e-05	0.000208	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—NQO1—hematologic cancer	2.04e-05	0.000208	CbGpPWpGaD
Olmesartan—Asthenia—Doxorubicin—hematologic cancer	2.03e-05	5.25e-05	CcSEcCtD
Olmesartan—Dizziness—Epirubicin—hematologic cancer	2.02e-05	5.23e-05	CcSEcCtD
Olmesartan—Pruritus—Doxorubicin—hematologic cancer	2e-05	5.18e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2e-05	0.000204	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL2RA—hematologic cancer	1.99e-05	0.000203	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IL2—hematologic cancer	1.97e-05	0.000201	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TERT—hematologic cancer	1.97e-05	0.0002	CbGpPWpGaD
Olmesartan—Vomiting—Epirubicin—hematologic cancer	1.94e-05	5.03e-05	CcSEcCtD
Olmesartan—Nausea—Methotrexate—hematologic cancer	1.94e-05	5.02e-05	CcSEcCtD
Olmesartan—Diarrhoea—Doxorubicin—hematologic cancer	1.93e-05	5.01e-05	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—CYCS—hematologic cancer	1.93e-05	0.000197	CbGpPWpGaD
Olmesartan—Rash—Epirubicin—hematologic cancer	1.92e-05	4.99e-05	CcSEcCtD
Olmesartan—Dermatitis—Epirubicin—hematologic cancer	1.92e-05	4.98e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—PDGFB—hematologic cancer	1.92e-05	0.000196	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—HSP90AA1—hematologic cancer	1.92e-05	0.000196	CbGpPWpGaD
Olmesartan—Headache—Epirubicin—hematologic cancer	1.91e-05	4.96e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—TSC2—hematologic cancer	1.87e-05	0.000191	CbGpPWpGaD
Olmesartan—Dizziness—Doxorubicin—hematologic cancer	1.87e-05	4.84e-05	CcSEcCtD
Olmesartan—Nausea—Epirubicin—hematologic cancer	1.81e-05	4.7e-05	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.81e-05	0.000185	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FGFR3—hematologic cancer	1.8e-05	0.000184	CbGpPWpGaD
Olmesartan—Vomiting—Doxorubicin—hematologic cancer	1.8e-05	4.65e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—MAPK14—hematologic cancer	1.79e-05	0.000182	CbGpPWpGaD
Olmesartan—Rash—Doxorubicin—hematologic cancer	1.78e-05	4.62e-05	CcSEcCtD
Olmesartan—Dermatitis—Doxorubicin—hematologic cancer	1.78e-05	4.61e-05	CcSEcCtD
Olmesartan—Headache—Doxorubicin—hematologic cancer	1.77e-05	4.59e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—ESR1—hematologic cancer	1.75e-05	0.000179	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FN1—hematologic cancer	1.73e-05	0.000177	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PIK3CG—hematologic cancer	1.73e-05	0.000176	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.73e-05	0.000176	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NFKBIA—hematologic cancer	1.71e-05	0.000174	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—BAD—hematologic cancer	1.71e-05	0.000174	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTP1—hematologic cancer	1.7e-05	0.000174	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NOTCH1—hematologic cancer	1.69e-05	0.000173	CbGpPWpGaD
Olmesartan—Nausea—Doxorubicin—hematologic cancer	1.68e-05	4.35e-05	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—CD80—hematologic cancer	1.66e-05	0.000169	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—KIT—hematologic cancer	1.66e-05	0.000169	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PIK3CG—hematologic cancer	1.66e-05	0.000169	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—NRAS—hematologic cancer	1.66e-05	0.000169	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.65e-05	0.000168	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PTPN11—hematologic cancer	1.63e-05	0.000166	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ABCB1—hematologic cancer	1.61e-05	0.000164	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CREBBP—hematologic cancer	1.6e-05	0.000163	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—MAPK3—hematologic cancer	1.59e-05	0.000162	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CREB1—hematologic cancer	1.58e-05	0.000161	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTM1—hematologic cancer	1.56e-05	0.000159	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—NCOR1—hematologic cancer	1.56e-05	0.000159	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—BRAF—hematologic cancer	1.56e-05	0.000159	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCL2—hematologic cancer	1.54e-05	0.000157	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL6R—hematologic cancer	1.54e-05	0.000157	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CREBBP—hematologic cancer	1.54e-05	0.000157	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PIK3CD—hematologic cancer	1.52e-05	0.000155	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ALB—hematologic cancer	1.5e-05	0.000153	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MAP2K1—hematologic cancer	1.47e-05	0.000149	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PIK3CD—hematologic cancer	1.46e-05	0.000148	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.44e-05	0.000147	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PIK3R1—hematologic cancer	1.43e-05	0.000146	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—KRAS—hematologic cancer	1.43e-05	0.000145	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FGF2—hematologic cancer	1.39e-05	0.000142	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—MTHFR—hematologic cancer	1.38e-05	0.000141	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PIK3R1—hematologic cancer	1.37e-05	0.00014	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—JAK2—hematologic cancer	1.34e-05	0.000136	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PIK3CB—hematologic cancer	1.32e-05	0.000135	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PIK3CA—hematologic cancer	1.31e-05	0.000134	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MDM2—hematologic cancer	1.3e-05	0.000133	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PIK3CB—hematologic cancer	1.27e-05	0.000129	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MTOR—hematologic cancer	1.27e-05	0.000129	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.22e-05	0.000124	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—HRAS—hematologic cancer	1.21e-05	0.000124	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CDKN1B—hematologic cancer	1.19e-05	0.000121	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—AKT1—hematologic cancer	1.18e-05	0.00012	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CASP3—hematologic cancer	1.17e-05	0.000119	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL2—hematologic cancer	1.17e-05	0.000119	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PIK3CG—hematologic cancer	1.16e-05	0.000118	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IL6—hematologic cancer	1.16e-05	0.000118	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PTEN—hematologic cancer	1.14e-05	0.000117	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCND1—hematologic cancer	1.14e-05	0.000116	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—JUN—hematologic cancer	1.13e-05	0.000116	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CDKN1A—hematologic cancer	1.1e-05	0.000112	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PTEN—hematologic cancer	1.1e-05	0.000112	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—EP300—hematologic cancer	1.09e-05	0.000111	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CREBBP—hematologic cancer	1.08e-05	0.00011	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MAPK8—hematologic cancer	1.07e-05	0.000109	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—AKT1—hematologic cancer	1.07e-05	0.000109	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—EP300—hematologic cancer	1.05e-05	0.000107	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PIK3CD—hematologic cancer	1.02e-05	0.000104	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SRC—hematologic cancer	1.02e-05	0.000104	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ALB—hematologic cancer	1.01e-05	0.000103	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—VEGFA—hematologic cancer	9.9e-06	0.000101	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—STAT3—hematologic cancer	9.81e-06	0.0001	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NRAS—hematologic cancer	9.78e-06	9.98e-05	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PIK3R1—hematologic cancer	9.64e-06	9.83e-05	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MAPK3—hematologic cancer	9.37e-06	9.56e-05	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MYC—hematologic cancer	9.11e-06	9.29e-05	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TGFB1—hematologic cancer	9.09e-06	9.27e-05	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PIK3CB—hematologic cancer	8.9e-06	9.07e-05	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—KRAS—hematologic cancer	8.42e-06	8.59e-05	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PIK3CA—hematologic cancer	8.07e-06	8.23e-05	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PIK3CA—hematologic cancer	7.73e-06	7.89e-05	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PTEN—hematologic cancer	7.69e-06	7.84e-05	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TP53—hematologic cancer	7.48e-06	7.63e-05	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—EP300—hematologic cancer	7.33e-06	7.48e-05	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HRAS—hematologic cancer	7.16e-06	7.3e-05	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL6—hematologic cancer	6.85e-06	6.99e-05	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—AKT1—hematologic cancer	6.59e-06	6.73e-05	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—AKT1—hematologic cancer	6.32e-06	6.45e-05	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PIK3CA—hematologic cancer	5.42e-06	5.53e-05	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—AKT1—hematologic cancer	4.43e-06	4.52e-05	CbGpPWpGaD
